The role of circulating adiponectin in prostate cancer: A meta-analysis

International Journal of Biological Markers

Volumn 30, Issue 1, 2015, Pages e22-e31

  Liao, Qiaofang ^a   Long, Chan ^a   Deng, Zhuojuan ^a   Bi, Xiaoxia ^a   Hu, Jun ^a  

^a Department of Hematology and Oncology   (China)

Author keywords

Adiponectin; Cancer; Prostate cancer; Systemic review

Indexed keywords

ADIPONECTIN; TUMOR MARKER;

BLOOD SAMPLING; BODY MASS; CANCER PATIENT; CANCER RISK; DISEASE ASSESSMENT; DOSE RESPONSE; HUMAN; META ANALYSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW (TOPIC); BLOOD; CASE CONTROL STUDY; MALE; PROSTATE TUMOR; RISK;

ADIPONECTIN; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK;

EID: 84930063379     PISSN: 03936155     EISSN: 17246008     Source Type: Journal    
DOI: 10.5301/jbm.5000124     Document Type: Review

References (39)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1): 11-30.
2. Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer. 2007; 109(6): 1192-1202.
3. Ma J, Li H, Giovannucci E, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancerspecific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 2008; 9(11): 1039-1047.
4. Freedland SJ, Williams CD, Masko EM. Adiponectin and prostate cancer mortality: to be or not to be skinny? Clin Chem. 2010; 56(1): 1-3.
5. Park J, Euhus DM, Scherer PE. Paracrine and endocrine effects of adipose tissue on cancer development and progression. Endocr Rev. 2011; 32(4): 550-570.
6. Lopez Fontana CM, Maselli Artola ME, Di Milta Monaco N, et al. [Influence of leptin and adiponectin on prostate cancer] [article in Spanish]. Arch Esp Urol. 2009; 62(2): 103-108.
7. Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S. Prostate cancer and adiponectin. Urology. 2005; 65(6): 1168-1172.
8. Michalakis K, Williams CJ, Mitsiades N, et al. Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev. 2007; 16: 308-313.
9. Grosman H, Fabre B, Mesch V, et al. Lipoproteins, sex hormones and inflammatory markers in association with prostate cancer. Aging Male. 2010; 13: 87-92.
10. Touvier M, Fezeu L, Ahluwalia N, et al. Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: a nested case-control study. Am J Epidemiol. 2013; 177(1): 3-13.
11. Tewari R, Rajender S, Natu SM, et al. Significance of obesity markers and adipocytokines in high grade and high stage prostate cancer in North Indian men: a cross-sectional study. Cytokine. 2013; 63(2): 130-134.
12. Baillargeon J, Platz EA, Rose DP, et al. Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer Epidemiol Biomarkers Prev. 2006; 15: 1331-1335.
13. Housa D, Vernerova Z, Heracek J, et al. Adiponectin as a potential marker of prostate cancer progression: studies in organ-confined and locally advanced prostate cancer. Physiological Research / Academia Scientiarum Bohemoslovaca. 2008; 57: 451-458.
14. Li H, Stampfer MJ, Mucci L, et al. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem. 2010; 56(1): 34-43.
15. Dhillon PK, Penney KL, Schumacher F, et al. Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2011; 20: 2618-2627.
16. López Fontana CM, Maselli ME, Pérez Elizalde RF, Di Milta Mónaco NA, Uvilla Recupero AL, López Laur JD. Leptin increases prostate cancer aggressiveness. J Physiol Biochem. 2011; 67(4): 531-538.
17. Al Khaldi RM, Al Mulla F, Al Awadhi S, Kapila K, Mojiminiyi OA. Associations of single nucleotide polymorphisms in the adiponectin gene with adiponectin levels and cardiometabolic risk factors in patients with cancer. Dis Markers. 2011; 30(4): 197-212.
18. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005; 5(1): 13.
19. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9): 603-605.
20. Bero L, Rennie D; The Cochrane Collaboration. Preparing, maintaining, and disseminating systematic reviews of the effects of health care. JAMA. 1995; 274(24): 1935-1938.
21. Orsini N, Li R, Wolk A, Khudyakov P, Spiegelman D. Metaanalysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. Am J Epidemiol. 2012; 175(1): 66-73.
22. Sher DJ, Oh WK, Jacobus S, Regan MM, Lee GS, Mantzoros C. Relationship between serum adiponectin and prostate cancer grade. Prostate. 2008; 68(14): 1592-1598.
23. Hsing AW, Deng J, Sesterhenn IA, et al. Body size and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev. 2000; 9(12): 1335-1341.
24. Albanes D, Weinstein SJ, Wright ME, et al. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst. 2009; 101(18): 1272-1279.
25. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006; 6(10): 772-783.
26. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care. 2003; 26(8): 2442-2450.
27. Saunders TJ, Palombella A, McGuire KA, Janiszewski PM, Despres JP, Ross R. Acute exercise increases adiponectin levels in abdominally obese men. J Nutr Metab. 2012; 2012: 148729.
28. Groeneveld MP, Huang-Doran I, Semple RK. Adiponectin and leptin in human severe insulin resistance: diagnostic utility and biological insights. Biochimie. 2012; 94(10): 2172-2179.
29. Ye J, Jia J, Dong S, et al. Circulating adiponectin levels and the risk of breast cancer: a meta-analysis. Eur J Cancer Prev. 2014; 23(3): 158-65.
30. Barb D, Neuwirth A, Mantzoros C., Balk SP. Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway. Endocr Relat Cancer. 2007; 14(4): 995-1005.
31. Xiang X, Saha AK, Wen R, Ruderman NB, Luo Z. AMPactivated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun. 2004; 321(1): 161-167.
32. Wang Y, Lam JB, Lam KS, et al. Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDAMB-231 cells in nude mice. Cancer Res. 2006; 66(23): 11462-11470.
33. Wang Y, Lam KS, Xu A. Adiponectin as a negative regulator in obesity-related mammary carcinogenesis. Cell Res. 2007; 17(4): 280-282.
34. Bub JD, Miyazaki T, Iwamoto Y. Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun. 2006; 340(4): 1158-1166.
35. Krämer HU, Schöttker B, Raum E, Brenner H. Type 2 diabetes mellitus and colorectal cancer: meta-analysis on sex-specific differences. Eur J Cancer. 2012; 48(9): 1269-1282.
36. Hivert MF, Sullivan LM, Shrader P, et al. Insulin resistance influences the association of adiponectin levels with diabetes incidence in two population-based cohorts: the Cooperative Health Research in the Region of Augsburg (KORA) S4/F4 study and the Framingham Offspring Study. Diabetologia. 2011; 54(5): 1019-1024.
37. Nayak BS, Marshall JR, Isitor G, Adogwa A. Hypoglycemic and hepatoprotective activity of fermented fruit juice of Morinda citrifolia (Noni) in diabetic rats. Evid Based Complement Alternat Med. 2011; 2011: 875293.
38. Tsao TS, Lodish HF, Fruebis J. ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol. 2002; 440(2-3): 213-221.
39. Jonathan D, Plenio MB. Light-shift-induced quantum gates for ions in thermal motion. Phys Rev Lett. 2001; 87(12): 127901.